A Study of the Need for Anticholinergic Medication in Patients Treated with Long-Term Antipsychotics

References

• Baker L. A., Cheng L. Y., Amara I. B. The withdrawal of benztropine mesylate in chronic schizophrenic patients. British Journal of Psychiatry 1983; 143: 584–90
   PubMed Web of Science ®Google Scholar
• Baldessarini R. J. Chemotherapy in Psychiatry. Harvard University Press, Cambridge, Mass 1977
   Google Scholar
• Cahan R. B., Parrish D. D. Reversibility of drug-induced parkinsonism. American Journal of Psychiatry 1960; 116: 1022–3
   PubMed Web of Science ®Google Scholar
• Cohen J. Handbook of Clinical Psychology. McGraw Hill, New York 1968; 101–6
   Google Scholar
• Crawshaw J. A., Mullen P. E. A study of Benzhexol abuse. British Journal of Psychiatry 1984; 145: 300–3
   PubMed Web of Science ®Google Scholar
• Di Mascio A., Dermirgian E. Antiparkinson drug overuse. Psychosomatics 1970; 11: 596–601
   PubMedGoogle Scholar
• Dixon W. J. BMDP Statistical Software. California University Press, Berkeley 1981
   Google Scholar
• Duvoisin R. The evaluation of extrapyramidal disease. Monoamines, Noyaux Gris Centraux et Syndrome de Parkinson. 1970; 313–25, Symposium Bel-Air, 4th Geneva, Georg (1971), Geneve
   Google Scholar
• Gardos G., Cole J. O. Tardive dyskinesia and anticholinergic drugs. American Journal of Psychiatry 1983; 140: 200–2
   PubMed Web of Science ®Google Scholar
• Hollister L. E. Psychopharmacology from Theory to Practice. Oxford Press, New York 1977
   Google Scholar
• Jellinek T., Gardos G., Cole J. O. Adverse effects of antiparkinson drug withdrawal. American Journal of Psychiatry 1981; 138: 1567–71
   PubMed Web of Science ®Google Scholar
• Johnstone E. C., Crow T. J., Ferrier I. N., et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine 1983; 13: 513–27
   PubMed Web of Science ®Google Scholar
• Keepers G. A., Clappison V. J., Casey D. E. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry 1983; 40: 1113–17
   PubMed Web of Science ®Google Scholar
• Klett C. J., Point P., Caffey E. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Archives of General Psychiatry 1972; 26: 374–9
   PubMed Web of Science ®Google Scholar
• Korczyn A. D., Goldberg G. J. Extrapyramidal effects of neuroleptics. Journal of Neurology, Neurosurgery and Psychiatry 1976; 39: 866–9
   PubMed Web of Science ®Google Scholar
• Lorr M., Vestre N. Psychotic Inpatient Profile Manual. University of Minnesota: Western Psychological Services. 1968
   Google Scholar
• McClelland H. A., Blessed G., Bhate S., Clarke P. A. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. British Journal of Psychiatry 1974; 124: 151–9
   PubMed Web of Science ®Google Scholar
• McInnis M., Petursson H. Trihexyphenidyl dependence. Acta Psychiatr Scand 1984; 69: 538–42
   PubMed Web of Science ®Google Scholar
• McInnis M., Petursson H. Withdrawal of trihexyphenidyl. Acta Psychiatr Scand 1985; 71: 297–303
   PubMed Web of Science ®Google Scholar
• Mandel W., Oliver W. A. Withdrawal of maintenance antiparkinson drug in the phenothiazine-induced extrapyramidal reaction. American Journal of Psychiatry 1961; 118: 351–2
   PubMed Web of Science ®Google Scholar
• Manos N., Gkiouzepas J., Logothetis J. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. American Journal of Psychiatry 1981; 138: 184–8
   PubMed Web of Science ®Google Scholar
• Menkes D., Caradoc-Davies G., Clarkson H., Mullen P. Anticholinergic equivalents and parkinsonism: A model for predicting the side effects of antipsychotic drugs, in preparation
   Google Scholar
• Orlov P., Kasparian G., Di Mascio A., Cole J. O. Withdrawal of antiparkinson drugs. Archives of General Psychiatry 1971; 25: 410–12
   PubMed Web of Science ®Google Scholar
• Owens D. G. C., Johnstone E. C., Frith C. D. Spontaneous involuntary disorders of movement. Archives of General Psychiatry 1982; 39: 452–61
   PubMedGoogle Scholar
• Rifkin A., Quitkin F., Kane J., et al. Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Archives of General Psychiatry 1978; 35: 483–9
   PubMed Web of Science ®Google Scholar
• St Jean A., Donald M. W., Ban T. A. Uses and abuses of antiparkinsonian medication. American Journal of Psychiatry 1964; 120: 801–3
   PubMed Web of Science ®Google Scholar
• Shader R. I., Greenblatt D. J. Uses and toxicity of Belladonna alkaloids and synthetic anticholinergics. Seminars in Psychiatry 1971; 3: 449–75
   PubMedGoogle Scholar
• Simpson G. M., Angus J. W. S. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Supplementum 1970; 212: 11–19
   PubMedGoogle Scholar
• Simpson G. M., Cooper T. B., Bark N., et al. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Archives of General Psychiatry 1980; 37: 205–8
   PubMed Web of Science ®Google Scholar
• Singh M. M., Kay S. R. Therapeutic reversal with benztropine in schizophrenics: Practical and theoretical significance. Journal of Nervous and Mental Disease 1975; 160: 258–66
   PubMed Web of Science ®Google Scholar
• Singh M. M., Smith J. M. Reversal of some therapeutic effects of an antipsychotic agent by an antiparkinsonian drug. Journal of Nervous and Mental Disease 1973; 157: 50–8
   PubMed Web of Science ®Google Scholar
• Swett C., Cole J. O., Shapiro S., Slone D. Extrapyramidal side effects in chlorpromazine recipients: Emergence according to benztropine prophylaxis. Archives of General Psychiatry 1977; 34: 942–3
   PubMed Web of Science ®Google Scholar
• Van Putten T. Why do schizoprenic patients refuse to take their drugs?. Archives of General Psychiatry 1974; 31: 67–72
   PubMed Web of Science ®Google Scholar